Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04517643 · ClinicalTrials.gov registry record · NA

TheraSphere® For Treatment of Metastases in Liver

A NA study of Colorectal Cancer and Colorectal Cancer Metastatic, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Completed
Registry status
NA
Development phase
4
Enrollment target
1
Study location

NCT04517643 is a NA study of Colorectal Cancer and Colorectal Cancer Metastatic that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 4 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04517643, a NA study of Colorectal Cancer and Colorectal Cancer Metastatic, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

COMPLETED
Registry status
NA
Development phase
4 participants
Enrollment target
1
Study location

Study Summary

To investigate whether the dose predicted by pre-therapy 99mTc MAA SPECT predicts the dose to the liver from the 90Y microspheres as assessed by post-therapy 90Y SPECT/CT or positron emission tomography (PET)/CT.

Interventions

  • OTHER Therasphere Therapy

Study Locations (1)

Maryland

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2020-11-12
Est. Completion 2022-12-01
Phase NA

What the Registry Record Tells You About NCT04517643

The ClinicalTrials.gov registry entry for NCT04517643 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Therasphere Therapy is the first listed.

NCT04517643 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04517643 about?

NCT04517643 is a clinical study titled "TheraSphere® For Treatment of Metastases in Liver". To investigate whether the dose predicted by pre-therapy 99mTc MAA SPECT predicts the dose to the liver from the 90Y microspheres as assessed by post-therapy 90Y SPECT/CT or positron emission tomography (PET)/CT.

What is the current status of trial NCT04517643?

This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2020-11-12. Estimated completion is 2022-12-01.

What conditions does trial NCT04517643 study?

This clinical trial studies the following conditions: Colorectal Cancer, Colorectal Cancer Metastatic.

What interventions are being tested in trial NCT04517643?

The interventions under investigation include: Therasphere Therapy (OTHER).

Who is sponsoring clinical trial NCT04517643?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04517643 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.